On the back of outstanding early sales traction for Remplir™ in Australia, New Zealand and Singapore, Orthocell has announced that it is accelerating its global expansion into multiple key jurisdictions.
Orthocell receives $3.18m R&D tax incentive refund
Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year.
Stockhead Special Report | Orthocell achieves third consecutive quarter of record revenue
Orthocell has been featured in a special report on Stockhead highlighting Orthocell’s consistent growth in sales of our regenerative medicine products, Striate+ and Remplir.
OCC Quarterly Report | Quarter ended 31 December 2024
Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter.
Podcast | Talk Ya Book
Orthocell Chairman John Van Der Wielen recently spoke with podcast host Chris Judd on Talk Ya Book to discuss the Company’s journey and exciting plans for global expansion with its regenerative medicine technologies.
The West Australian | Orthocell cracks a new record high
Orthocell has been featured in The West Australian in an article by Sean Smith titled “Orthocell cracks a new record high.”
Orthocell Submits U.S. FDA Regulatory Application
Orthocell has announced the submission of its U.S. FDA 510(k) regulatory application for clearance to commercially distribute Remplir™ into the US$1.6 billion 1 U.S. nerve repair market.
Podcast | Frazis Capital Podcast
Orthocell CEO & MD, Paul Anderson, recently joined Micahel Frazis on the Frazis Capital Podcast.
Orthocell Achieves Major Milestone with First Sales of Remplir™ in Singapore
Orthocell has today announced the achievement of first sales of Remplir™ in Singapore, marking another significant milestone in its global commercialisation strategy.
The Australian Financial Review | Perth’s billionaires pile into medtech Orthocell
Orthocell has been featured in The Australian Financial Review in an article by Health Editor Michael Smith titled “Perth’s billionaires pile into medtech Orthocell”.